Drugs / PK101-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03553316 | Feb → Mar 2019 | arthritic joint disease | PMG Pharm Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04858659 Comparator | May 2021 → Mar 2022 | osteoarthritis, knee | PMG Pharm Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PK101-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03553316 ↗ |